Eric Johnston, Cantor Fitzgerald chief equity and macro strategist, joins 'Money Movers' to discuss Johnston's thesis for ...

In a recent blog post, OpenAI CEO Sam Altman said that as OpenAI continues to advance it has moved beyond research to product ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, ...

In a report released yesterday, Ross Osborn from Cantor Fitzgerald reiterated a Buy rating on Avita Medical (RCEL – Research Report), with a ...

Two Israeli stocks have been included in the top picks 2025 lists of US analysts. Bank of America chose Teva Pharmaceutical ...

Cantor Fitzgerald began coverage on shares of Anteris Technologies Global (NASDAQ:AVR – Free Report) in a report issued on Tuesday morning, Marketbeat Ratings reports. The firm issued an overweight ...

Cantor Fitzgerald has recently initiated Aquestive Therapeutics Inc (AQST) stock to Overweight rating, as announced on December 17, 2024, according to Finviz. Earlier, on May 10, 2024, Leerink ...

Humacyte Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -19.04%. The profit margin, also known as the revenue ratio or gross profit ratio, measures ...

KeyCorp upgraded shares of Acadia Healthcare (NASDAQ:ACHC – Free Report) from a sector weight rating to an overweight rating ...

Cantor Fitzgerald Equity Opportunity Fd earns a Low Process Pillar rating. The primary detractor from the rating is the fund's unimpressive long-term risk-adjusted performance. This can be seen in ...

Fidelity is calling it: governments and nation-states are about to get serious about Bitcoin. In a new report, the investment ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...